#United States #Specialty Pharmacy #Florham Park #Asembia #David Skomo

Asembia Appoints David Skomo as CEO

Asembia, recognized as a front-runner in technology-enabled commercialization solutions for the specialty pharmaceutical sector, has announced a significant leadership change with the appointment of David Skomo as Chief Executive Officer. Succeeding Larry Irene, one of the company's co-founders, Skomo is set to steer Asembia into a new era of growth and innovation.

In his new role, David Skomo, who brings over 30 years of extensive experience in specialty pharmacy and pharmaceuticals, will concentrate on enhancing Asembia's capabilities in commercial operations, technology, and pharmacy services. His appointment is seen as a crucial step as the company aims to broaden its impact across the pharmaceutical landscape, particularly for patients, prescribers, and pharmacies.

Skomo's diverse background includes notable experiences in high-ranking positions at WellDyne, OptumRx, CVS, and Diplomat. Most recently, he served as the Chief Operating Officer and Division President of HealthDyne at WellDyne. His journey has equipped him with a comprehensive understanding of the specialty pharmacy ecosystem, making him a fitting leader for Asembia's ambitions.

Speaking on his appointment, Skomo expressed excitement about the future: "I am honored to join Asembia at such an exciting time for the company and the specialty pharma industry. I want to thank Larry for his leadership and vision for Asembia's growth. I look forward to working with the talented employees, customers, and partners to build on Asembia's remarkable foundation and accelerate innovation to create greater value across the specialty pharma ecosystem.”

This shift in leadership arrives at a pivotal moment as Asembia continues to emphasize its commitment to improving patient access to innovative drug therapies. Under Skomo's guidance, Asembia will not only strive for organic growth but also consider strategic acquisitions that align with its goals. This strategic approach is expected to bolster the company’s operational initiatives and expand its market reach.

Spencer Moore, a member of the Asembia Board, commented on the leadership transition, stating, “David's experience, passion, and deep understanding of the specialty pharma ecosystem make him the right leader for Asembia's next chapter of growth. We are confident that, under David's leadership, Asembia will continue to innovate, grow, and deliver meaningful value for patients, pharmacies, and pharma companies.”

About Asembia

Headquartered in Florham Park, New Jersey, Asembia specializes in providing comprehensive technology-enabled solutions aimed at facilitating commercialization for specialty pharma, catering not only to pharmaceutical manufacturers but also to pharmacies, patients, and prescribers. Their offerings include patient support HUB services, specialty distribution, data services, pharmacy software, and group purchasing solutions.

Asembia's unique position in the industry enables it to connect stakeholders through a tailored approach to value creation, significantly improving therapy access and enhancing the experiences of millions of patients each year. For further details about Asembia and their services, visit www.asembia.com.